Handelsbanken Fonder Ab Neurocrine Biosciences Inc Transaction History

Handelsbanken Fonder Ab

$24.3 Billion
Q1 2025

A detailed history of Handelsbanken Fonder Ab transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 86,067 shares of NBIX stock, worth $10.6 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

86,067

Previous 26,867 220.34%

Holding current value

$10.6 Million

Previous $3.67 Million 159.59%

% of portfolio

0.04%

Previous 0.01%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 15, 2025	BUY	$107.22 - $153.29 $6.35 Million - $9.07 Million	59,200 Added 220.34%	86,067 $9.52 Million
Q3 2024 Oct 04, 2024	BUY	$114.58 - $153.15 $527,068 - $704,490	4,600 Added 20.66%	26,867 $3.1 Million
Q2 2024 Aug 05, 2024	SELL	$130.86 - $143.19 $104,688 - $114,552	-800 Reduced 3.47%	22,267 $3.07 Million
Q1 2024 May 13, 2024	BUY	$130.4 - $143.74 $547,680 - $603,708	4,200 Added 22.26%	23,067 $3.18 Million
Q4 2023 Feb 01, 2024	BUY	$106.07 - $132.76 $159,105 - $199,140	1,500 Added 8.64%	18,867 $2.49 Million
Q2 2023 Aug 02, 2023	SELL	$89.53 - $104.87 $17,906 - $20,974	-200 Reduced 1.14%	17,367 $1.64 Million
Q1 2023 Apr 28, 2023	BUY	$94.11 - $123.02 $414,084 - $541,288	4,400 Added 33.42%	17,567 $1.78 Million
Q4 2022 Feb 07, 2023	SELL	$106.72 - $127.06 $224,112 - $266,826	-2,100 Reduced 13.76%	13,167 $1.57 Million
Q1 2022 May 11, 2022	BUY	$72.45 - $94.81 $369,495 - $483,531	5,100 Added 50.16%	15,267 $1.43 Million
Q4 2021 Feb 08, 2022	SELL	$79.65 - $106.22 $581,445 - $775,406	-7,300 Reduced 41.79%	10,167 $866,000
Q2 2021 Aug 03, 2021	SELL	$89.43 - $102.27 $53,658 - $61,362	-600 Reduced 3.32%	17,467 $1.7 Million
Q4 2020 Feb 11, 2021	SELL	$86.91 - $108.33 $17.5 Million - $21.9 Million	-201,900 Reduced 91.79%	18,067 $1.73 Million
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $1.92 Million - $2.7 Million	20,000 Added 10.0%	219,967 $21.2 Million
Q2 2020 Aug 13, 2020	SELL	$85.09 - $130.36 $343,167 - $525,741	-4,033 Reduced 1.98%	199,967 $24.4 Million
Q1 2020 May 14, 2020	BUY	$75.11 - $113.76 $2.63 Million - $3.98 Million	35,000 Added 20.71%	204,000 $17.7 Million
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $3.04 Million - $4.15 Million	-35,000 Reduced 17.16%	169,000 $18.2 Million
Q3 2019 Oct 31, 2019	BUY	$83.82 - $101.5 $2.26 Million - $2.74 Million	27,000 Added 15.25%	204,000 $18.4 Million
Q2 2019 Jul 12, 2019	SELL	$72.24 - $91.27 $2.17 Million - $2.74 Million	-30,000 Reduced 14.49%	177,000 $14.9 Million
Q1 2019 May 10, 2019	BUY	$69.31 - $91.53 $457,446 - $604,098	6,600 Added 3.29%	207,000 $18.2 Million
Q4 2018 Jan 31, 2019	BUY	$68.32 - $124.36 $2.42 Million - $4.4 Million	35,400 Added 21.45%	200,400 $14.3 Million
Q3 2018 Oct 19, 2018	BUY	$98.88 - $125.85 $494,400 - $629,250	5,000 Added 3.13%	165,000 $20.3 Million
Q2 2018 Jul 11, 2018	SELL	$75.3 - $105.99 $451,800 - $635,940	-6,000 Reduced 3.61%	160,000 $15.7 Million
Q1 2018 May 18, 2018	BUY	$75.88 - $92.43 $1.1 Million - $1.34 Million	14,500 Added 9.57%	166,000 $13.8 Million
Q4 2017 Feb 08, 2018	BUY	$58.53 - $77.59 $204,855 - $271,565	3,500 Added 2.36%	151,500 $11.8 Million
Q3 2017 Oct 24, 2017	BUY	$47.97 - $61.28 $7.1 Million - $9.07 Million	148,000	148,000 $9.07 Million

Others Institutions Holding NBIX

# of Institutions

650

Shares Held

97.2M

Call Options Held

749K

Put Options Held

553K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.8B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.

Account

Handelsbanken Fonder Ab Neurocrine Biosciences Inc Transaction History